These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36878571)

  • 1. New therapies for clear cell ovarian carcinoma.
    Stewart J; Cunningham N; Banerjee S
    Int J Gynecol Cancer; 2023 Mar; 33(3):385-393. PubMed ID: 36878571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.
    Liu Z; Jing C; Kong F
    J Ovarian Res; 2024 Feb; 17(1):39. PubMed ID: 38347608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
    Lapke N; Chen CH; Chang TC; Chao A; Lu YJ; Lai CH; Tan KT; Chen HC; Lu HY; Chen SJ
    BMC Cancer; 2021 May; 21(1):499. PubMed ID: 33947352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future strategies for treatment of ovarian clear cell carcinoma.
    Ogasawara A; Sato S; Hasegawa K
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
    Fujiwara S
    Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
    Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
    Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
    Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
    Nagasawa S; Ikeda K; Horie-Inoue K; Sato S; Takeda S; Hasegawa K; Inoue S
    Endocr J; 2020 Feb; 67(2):219-229. PubMed ID: 31748433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathogenesis of ovarian clear cell carcinoma.
    Gounaris I; Brenton JD
    Future Oncol; 2015; 11(9):1389-405. PubMed ID: 25952785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gadducci A; Multinu F; Cosio S; Carinelli S; Ghioni M; Aletti GD
    Gynecol Oncol; 2021 Sep; 162(3):741-750. PubMed ID: 34247767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
    Kuroda Y; Chiyoda T; Kawaida M; Nakamura K; Aimono E; Yoshimura T; Takahashi M; Saotome K; Yoshihama T; Iwasa N; Sakai K; Yamagami W; Nishihara H; Aoki D
    Gynecol Oncol; 2021 Sep; 162(3):679-685. PubMed ID: 34272091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
    Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational genomics of ovarian clear cell carcinoma.
    Khalique S; Lord CJ; Banerjee S; Natrajan R
    Semin Cancer Biol; 2020 Apr; 61():121-131. PubMed ID: 31698086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
    Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Kawahara N; Yamada Y; Kobayashi H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian Clear Cell Carcinoma: Genomic Characterization, Pathogenesis and Targeted Therapy.
    Xie Y; Kong W; Luo D; Chen S; Zhao X; Zhang HE
    Anticancer Res; 2023 Aug; 43(8):3401-3410. PubMed ID: 37500149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.